Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Novartis Great Lakes Drug Development, Inc. Integrium |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00817414 |
This study will determine the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in patients with hypertension
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Placebo Drug: LCI699 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment |
Official Title: | A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension |
Estimated Enrollment: | 63 |
Study Start Date: | December 2008 |
Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Cohort A, Placebo: Placebo Comparator | Drug: Placebo |
Cohort A, LCI699 dosing regimen 1: Experimental | Drug: LCI699 |
Cohort A, LCI699 dosing regimen 2: Experimental | Drug: LCI699 |
Cohort B, Placebo: Placebo Comparator | Drug: Placebo |
Cohort B, LCI699 dosing regimen 3: Experimental | Drug: LCI699 |
Cohort B, LCI699 dosing regimen 4: Experimental | Drug: LCI699 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Long Beach Center for Clinical Research | |
Long Beach, California, United States, 90806 | |
Impact Clinical Trials | |
Beverly Hills, California, United States, 90211 | |
Innovative Clinical Research, Inc | |
Harbor City, California, United States, 90710 | |
Associated Pharmaceutical Research Center, Inc | |
Buena Park, California, United States, 90620 | |
United States, Colorado | |
Metro Clinical Research | |
Littleton, Colorado, United States, 80120 | |
United States, North Carolina | |
Clinical Study Center of Asheville, LLC | |
Asheville, North Carolina, United States, 28801 | |
Northstate Clinical Research | |
Lenior, North Carolina, United States, 28645 | |
United States, Pennsylvania | |
Tipton Medical & Diagnostic Center | |
Tipton, Pennsylvania, United States, 16684 | |
United States, Texas | |
dgd Research, Inc | |
San Antonio, Texas, United States, 78229 | |
Punzi Medical Center | |
Carollton, Texas, United States, 75006 | |
Iceland, SA | |
Encode Clinic | |
Reykjavik, SA, Iceland |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CLCI699A2215, EudraCT 2008-007337-49 |
Study First Received: | January 5, 2009 |
Last Updated: | July 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00817414 History of Changes |
Health Authority: | United States: Food and Drug Administration; Iceland: Icelandic Medicines Control Agency |
Blood Pressure Hypertension Cortisol |
Anti-Inflammatory Agents Hydrocortisone Cortisol succinate |
Vascular Diseases Hydrocortisone acetate Hypertension |
Anti-Inflammatory Agents Hydrocortisone Therapeutic Uses Vascular Diseases |
Cardiovascular Diseases Pharmacologic Actions Hypertension |